Chronic Migraine
Conditions
Brief summary
Cathodal tDCS decreases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in chronic migraine.
Detailed description
During the interictal phase, the cerebral cortex is characterised by a hyperresponsiveness to repeated sensory stimuli, manifested by a lack of habituation or adaptation of cortical responses. Lack of habituation has been shown in the visual cortex in studies of visual evoked potentials (VEP) during the interictal period and it is possibly explained by a reduction in the cortical pre-activation level due to thalamo-cortical dysrhythmia. Just before and during the migraine attack, cortical reactivity changes drastically: habituation is restored and the amplitude increases. In chronic migraine (headache occurring on 15 or more days per month for more than 3 months with features of migraine headache on at least 8 days per month), VEPs habituate normally like those recorded during attacks of episodic migraine, but have in addition an increased amplitude in the 1st block of responses. Chronic migraine was therefore compared to a never ending migraine attack accompanied by cortical hypersensitivity. In this study the investigators aim to demonstrate that cathodal tDCS over the visual cortex with simultaneous anodal tDCS over the left dorsolateral prefrontal cortex is able: 1) to reduce cortical hypersensitivity and habituation as assessed by VEPs and contact heat evoked nociceptive potentials (CHEPS), as well as to decrease pain perception assessed by quantitative sensory testing (QST) and the nociceptive blink reflex (nBR); 2) to decrease headache and migraine frequency.
Interventions
DEVICECefaly tDCS
Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
Sponsors
University of Liege
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of chronic migraine (ICHD III beta 1.3) with or without medication overuse
Exclusion criteria
* others diseases or contraindications to tDCS (epilepsy, pacemaker, metal prosthetics)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Migraine frequency | 6 months | The investigators evaluate migraine frequency at baseline, during the treatment and 2 months after its end. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Migraine intensity | 6 months | The investigators evaluate migraine intensity at baseline, during the treatment and 2 months after its end. |
| Acute medication intake | 6 months | The investigators evaluate acute medication intake at baseline, during the treatment and 2 months after its end. |
| Attack duration | 6 months | The investigators evaluate attack duration at baseline, during the treatment and 2 months after its end. |
| Scores at psychological scales | 6 months | The investigators evaluate scores at psychological scales at baseline, during the treatment and 2 months after its end. |
Countries
Belgium
Outcome results
None listed